• February 14, 2017 at 3:35 pm #1218

    Cocrystal Pharma, Inc. (COCP), a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus (HCV), Influenza virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The company was founded in 2007 and is headquartered in Tucker, Georgia.

    [stock-quotes-list symbols=”COCP” stockExchange=”OTCBB” width=”100%” height=”380″ motif=”financial” palette=”financial-light” includeChart=”true”]

    • This topic was modified 1 year ago by PennyPicks.
    • This topic was modified 11 months, 3 weeks ago by PennyPicks.

You must be logged in to reply to this topic.